Dear Valued Visitor,

We have noticed that you are using an ad blocker software.

Although advertisements on the web pages may degrade your experience, our business certainly depends on them and we can only keep providing you high-quality research based articles as long as we can display ads on our pages.

To view this article, you can disable your ad blocker and refresh this page or simply login.

We only allow registered users to use ad blockers. You can sign up for free by clicking here or you can login if you are already a member.

Here is What Hedge Funds Think About Rofin-Sinar Technologies (RSTI)

Page 1 of 2

Is it smart to be bullish on Rofin-Sinar Technologies (NASDAQ:RSTI)?

At the moment, there are dozens of methods market participants can use to track publicly traded companies. Some of the best are hedge fund and insider trading movement. At Insider Monkey, our studies have shown that, historically, those who follow the best picks of the elite investment managers can trounce the broader indices by a very impressive margin (see just how much).

Equally as necessary, optimistic insider trading activity is a second way to look at the financial markets. Obviously, there are plenty of stimuli for a corporate insider to downsize shares of his or her company, but just one, very simple reason why they would buy. Several empirical studies have demonstrated the valuable potential of this method if “monkeys” understand what to do (learn more here).

Now that that’s out of the way, we’re going to study the recent info surrounding Rofin-Sinar Technologies (NASDAQ:RSTI).

How have hedgies been trading Rofin-Sinar Technologies (NASDAQ:RSTI)?

At Q2’s end, a total of 8 of the hedge funds we track held long positions in this stock, a change of 14% from the first quarter. With hedgies’ positions undergoing their usual ebb and flow, there exists a select group of key hedge fund managers who were boosting their holdings significantly.

Rofin-Sinar Technologies (NASDAQ:RSTI)When using filings from the hedgies we track, Royce & Associates, managed by Chuck Royce, holds the most valuable position in Rofin-Sinar Technologies (NASDAQ:RSTI). Royce & Associates has a $51 million position in the stock, comprising 0.2% of its 13F portfolio. Sitting at the No. 2 spot is Matt McLennan of First Eagle Investment Management, with a $46.5 million position; 0.1% of its 13F portfolio is allocated to the stock. Remaining hedgies that are bullish include Martin Whitman’s Third Avenue Management, Mario Gabelli’s GAMCO Investors and Joel Greenblatt’s Gotham Asset Management.

Consequently, certain bigger names have jumped into Rofin-Sinar Technologies (NASDAQ:RSTI) headfirst. Royce & Associates, managed by Chuck Royce, initiated the biggest position in Rofin-Sinar Technologies (NASDAQ:RSTI). Royce & Associates had 51 million invested in the company at the end of the quarter. Matt McLennan’s First Eagle Investment Management also made a $46.5 million investment in the stock during the quarter. The following funds were also among the new RSTI investors: Martin Whitman’s Third Avenue Management, Mario Gabelli’s GAMCO Investors, and Joel Greenblatt’s Gotham Asset Management.

How are insiders trading Rofin-Sinar Technologies (NASDAQ:RSTI)?

Insider buying made by high-level executives is at its handiest when the company we’re looking at has experienced transactions within the past 180 days. Over the last half-year time frame, Rofin-Sinar Technologies (NASDAQ:RSTI) has seen zero unique insiders purchasing, and zero insider sales (see the details of insider trades here).

We’ll check out the relationship between both of these indicators in other stocks similar to Rofin-Sinar Technologies (NASDAQ:RSTI). These stocks are Analogic Corporation (NASDAQ:ALOG), Measurement Specialties, Inc. (NASDAQ:MEAS), MTS Systems Corporation (NASDAQ:MTSC), FARO Technologies, Inc. (NASDAQ:FARO), and Badger Meter, Inc. (NYSE:BMI). This group of stocks are the members of the scientific & technical instruments industry and their market caps resemble RSTI’s market cap.

Page 1 of 2

Biotech Stock Alert - 20% Guaranteed Return in One Year

Hedge Funds and Insiders Are Piling Into

One of 2015's best hedge funds and two insiders snapped up shares of this medical device stock recently. We believe its transformative and disruptive device will storm the $3+ billion market and help it achieve 500%-1000% gains in 3 years.

Get your FREE REPORT and the details of our 20% return guarantee today.

Subscribe me to Insider Monkey's Free Daily Newsletter
This is a FREE report from Insider Monkey. Credit Card is NOT required.
Loading Comments...

Thanks! An email with instructions is sent to !

Your email already exists in our database. Click here to go to your subscriptions

Insider Monkey returned 102% in 3 years!! Wondering How?

Download a complete edition of our newsletter for free!